COMMUNIQUÉS West-GlobeNewswire

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
27/07/2026
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
27/07/2026
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a [...]
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
27/07/2026
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with [...]
Cato Healthcare Supply Appoints Ryan F. Zackon as President and Chief Executive Officer
27/07/2026
Experienced Supply Chain Leader Strengthens Executive Leadership Team to Accelerate Growth, Innovation, and International Expansion DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, a leading healthcare [...]
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
27/07/2026
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready third- [...]
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
27/07/2026
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]
Flourish Health Raises $46M to Scale Intensive Mental Health Care for Youth in Crisis
27/07/2026
Funding fuels national expansion of model that delivers proven outcomes for high-acuity kids through psychiatrist-led Care Pods and an AI-enabled care delivery platform RICHMOND, Va., July 27, 2026 (GLOBE NEWSWIRE) -- [...]
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
27/07/2026
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence [...]
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026
Exclusive partnership provides 319 Golf Society members with preferred Flyte benefits. FLYTE brings its regional luxury private aviation platform to members of premier private golf clubs across the United States FORT [...]
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27/07/2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical- [...]
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
27/07/2026
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles [...]
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet [...]
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
27/07/2026
Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ , is pleased to share this update on the meaningful advancements the [...]
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs
27/07/2026
Reintroduction reflects clinician input and Curium investments to support reliable, long-term U.S. supply BOSTON, July 27, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today the immediate reintroduction of Thallous [...]
Cristcot Presents Poster and Select Oral Presentation for Implementing Endocrine Principles to Assess Safety and Compliance within a Clinical Trial at ENDO 2026
27/07/2026
-- Study findings create a framework of protocols for implementing endocrine principles to assess compliance within a clinical trial that can be deployed across medical specialties -- -- Building in hypothalamic- [...]
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
27/07/2026
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of [...]

Pages